Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 6/20 | 0.50 |
| ▸ | PNP | P00491 | 8/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10508281 | 0.88 | HPRT1 (0.49) | HPRT1PNPTYMS | |
| SCHEMBL10506935 | 0.88 | MAPT (0.50) | HPRT1PNPTYMS | |
| SCHEMBL9798195 | 0.88 | HPRT1 (0.47) | HPRT1PNP | |
| SCHEMBL10506438 | 0.87 | HPRT1 (0.48) | HPRT1TYMSNOS1 | |
| SCHEMBL10506884 | 0.87 | HPRT1 (0.48) | HPRT1TYMS | |
| SCHEMBL10506681 | 0.87 | HPRT1 (0.48) | HPRT1PNPTYMSNOS1 | |
| SCHEMBL10507491 | 0.84 | HPRT1 (0.46) | HPRT1TYMSNOS1 | |
| SCHEMBL10507502 | 0.84 | TYMS (0.51) | HPRT1PNPTYMS | |
| SCHEMBL10508847 | 0.84 | TYMS (0.51) | HPRT1PNPTYMSQTRT1 | |
| SCHEMBL9798165 | 0.84 | HPRT1 (0.47) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241601-A | 6-Phenyl-2, 2' -bipyridine platinum (II) -guanine nitrogen heterocyclic carbene complex, and preparation method and application thereof | 南京林业大学 | 2025-01-03 | — | — | CN | disclosed |
| CN-116003478-A | Terpyridine-platinum (II) novel complex containing guanine derivative ligand, and preparation method and application thereof | 中国药科大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-113480539-B | Synthetic method of nitric acid catalyzed hypoxanthine derivative | 新乡学院 | 2023-03-31 | — | — | CN | disclosed |
| CN-113480539-A | Synthetic method of nitric acid catalyzed hypoxanthine derivative | 新乡学院 | 2021-10-08 | — | — | CN | disclosed |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2019-03-21 | — | — | US | disclosed |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Biocodex, Inc (US) | 2014-01-30 | — | — | US | disclosed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| CN-100500664-C | Imidazole [1,2-alpha] purine derivative, method of producing same and use thereof | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-06-17 | — | — | CN | disclosed |
| EP-1848717-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Topotarget A/S (DK) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006085219-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| WO-2000006573-A1 | ANTIVIRAL ALKYL SUBSTITUTED PURINE DERIVATIVES AND THEIR PREPARATION | Kemijski inštitut (SI) | 2000-02-10 | — | — | WO | disclosed |
| EP-0464112-B1 | A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS | GEA FARMACEUTISK FABRIK AS (DK) | 1994-10-05 | — | — | EP | disclosed |
| US-5223619-A | Catalytic cyclization | A/S GEA FARMACEUTISK FABRIK (DK) | 1993-06-29 | — | — | US | disclosed |
| EP-0464112-A1 | A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS. | GEA FARMACEUTISK FABRIK AS (DK) | 1992-01-08 | — | — | EP | disclosed |
| WO-1990011283-A1 | A PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED GUANINE DERIVATIVES AND INTERMEDIATES FOR USE IN THE PROCESS | A/S GEA FARMACEUTISK FABRIK (DK) | 1990-10-04 | — | — | WO | disclosed |
| US-4874862-A | Process for preparing guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0156559-B1 | 8-SUBSTITUTED GUANINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4748177-A | Guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0156559-A2 | 8-Substituted guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP2B, TOP1 | HPRT1 11/4885PNP 6/4885TYMS 9/4885 |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | HPRT1 50/4885PNP 13/4885TYMS 27/4885 |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | HPRT1 51/4885PNP 13/4885TYMS 29/4885 |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | HPRT1 42/4885PNP 10/4885TYMS 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.